Science Library · Guide
How to Read a Peptide Certificate of Analysis (COA)
How to read a peptide Certificate of Analysis (COA): identity, purity, content, methods, red flags, and what a COA does not establish. Research use only.
What is a peptide Certificate of Analysis?
A peptide Certificate of Analysis (COA) is a sample-specific analytical report: it records which tests a laboratory performed on the material it received, and what those tests measured [2][3]. Read literally, it shows the identity evidence, purity or impurity profile, and quantity or net peptide content that were part of the ordered analysis — and it shows nothing about attributes nobody analyzed. It is a measurement record, not a marketing certificate or a blanket quality guarantee.
Three elements make the numbers on the page mean anything: identifiers tying the report to your material, method information sufficient to interpret each result, and a clear statement of the ordered scope [2]. Without them, a percentage is a figure with no question attached.
Where the ordered service supports it, a report also carries orthogonal information — identity evidence read alongside impurity profile and content [3][4]. Even a thorough COA does not prove safety, sterility, clinical efficacy, or legality unless those properties were specifically tested and reported.
What a COA is for: traceability and scoped reporting
A certificate exists to connect two things that are otherwise easy to separate: a physical sample and a set of numbers. Traceability is that connection — identifiers, receipt and analysis dates, and laboratory attribution together let a reader say which material produced which result, and when [2]. A report that cannot be tied back to a specific sample is not usable as evidence about that sample, however sound its chemistry.
The second purpose is scoped reporting. A COA documents the tests that were ordered and performed, which also means it silently defines everything it does not cover. Specification frameworks are built around this pairing: each attribute has its own test procedure and its own acceptance criterion, rather than one overall verdict standing in for all of them [2][3]. Reading the scope first is what keeps the rest of the document from being over-read.
This is also why a COA is not a specification sheet. A specification states what material is supposed to meet; a certificate states what one sample was observed to be, on one date, under stated methods. Treating the two as interchangeable turns a measurement into a promise it never made.
Supplier COA vs independent third-party testing
Many peptides ship with a supplier-generated COA tied to the seller’s manufacturing or QC process. Independent third-party testing analyzes a sample you submit — often after receipt — under a catalog service with its own method and scope.
Both can be sample-specific, but independence matters when you need analytical evidence separate from the seller’s commercial interest. Compare scope, methods, and identifiers rather than treating any COA as interchangeable.
COA anatomy — header and metadata
If identifiers are missing or generic, ask how the report maps to your physical sample before relying on numerical results.
- Sample name, client sample ID, or lot/batch reference linking report to material
- Report date and, when stated, analysis or receipt dates
- Laboratory or reporting entity attribution
- Method references or brief method descriptions
- Signature or electronic release indicators when provided
Identity section
Identity fields typically report observed molecular mass from LC-MS, sometimes with charge states or deconvoluted intact mass [4]. MS/MS fragmentation may appear when sequence confirmation is part of the ordered analysis [4]. Compare observed values to theoretical mass for the intended sequence with the tolerance stated on the report.
Identity data do not replace a purity method. They address whether the observed material is consistent with the intended analyte — not how dominant it is among impurities [3][6].
How to interpret HPLC information on a COA
The chromatographic block on a report is method information rather than a result, and it is what makes the purity figure interpretable. Look for the separation mode and column chemistry, the mobile phases and gradient in outline, the detection wavelength, and — most importantly — the integration basis used to decide which peaks entered the calculation [7][4]. A reporting or integration threshold, where stated, tells you what “not detected” meant on this particular run [6].
Two habits help here. First, treat the percentage as bound to its method: purity figures produced under different columns, gradients, or integration rules are not directly comparable across reports [7]. Second, check whether the report shows a peak table, a chromatogram image, or both — a picture without integration rules does not define a purity number, and a number without a method leaves you unable to reproduce or challenge it [4].
Where a system suitability or method reference line appears, read it as evidence that the separation was operating within its own defined expectations, not as a statement about the material [7]. Deeper treatment of chromatographic principles sits in our resource on HPLC and LC-MS for peptide testing.
How to interpret LC-MS information on a COA
Mass spectrometry fields answer a different question, so they are read differently. The useful comparison is between an observed mass and the theoretical mass for the intended sequence, within the tolerance the report states [4][8]. Charge-state or deconvolution notes indicate how the reported intact mass was derived from raw ion data, which matters because a mass reported without that context is harder to check [8].
Before concluding that an observed mass disagrees, confirm the theoretical value you are comparing against. Terminal chemistry such as a C-terminal amide versus a free acid, salt or adduct assumptions, and modifications such as oxidation each shift the expected number, and these account for a meaningful share of apparent identity mismatches [6][8]. When MS/MS is part of the ordered analysis, fragmentation evidence localizes agreement to sequence regions rather than resting on total mass alone [8].
The boundary is worth stating plainly: mass agreement supports identity, it does not measure how much of the sample that identified species represents. Species sharing the same nominal mass — including some isomeric or positional variants — can be indistinguishable by intact mass alone [8][6].
Purity and impurity section
Purity results usually derive from RP-HPLC/UPLC with UV detection: retention time of the main peak, chromatogram image or peak table, area percent, and detection wavelength [6][4]. Integration rules define which peaks count — without them, the percentage is not fully interpretable [4].
Impurity peaks may represent deletion sequences, oxidized forms, or other related species detectable under the method [6]. For certain synthetic peptide ANDAs that refer to listed drugs of rDNA origin, FDA guidance historically emphasized impurity-profile comparison to the reference listed drug as a quality consideration for that pathway [1]. The purity section does not automatically report every impurity class — only those detected and integrated per the stated method.
Content and quantity section
When net peptide content (NPC), assay, or amino acid analysis results appear, they address peptide mass fraction — distinct from chromatographic area percent [3][4]. Units matter: per milligram of powder, per vial, or per stated label mass [4].
If your COA lacks a content field but your calculations require peptide mass, see our explainer on peptide purity vs peptide content before assuming HPLC purity equals mass fraction.
Telling purity and content apart on the page
These are the two fields most often read as if they were one. Both are percentages, they frequently sit within a few lines of each other, and only the field label and units distinguish them.
A practical test before using either figure: name the quantity your calculation needs, then find the field whose units express that quantity. Molarity and other mass-based calculations need peptide mass, so they need a content value with an explicit basis [4][3]. Assessments of impurity burden need area percent read together with its integration rules [6][7].
The two numbers are not expected to agree, and the size of the gap between them tracks how much counterion and residual moisture the material carries rather than how carefully it was made [6][4]. Our explainer on peptide purity vs peptide content works through that arithmetic and the mass-balance reasoning behind it.
| On the report | Chromatographic purity | Net peptide content |
|---|---|---|
| Typical field wording | “Purity by HPLC”, “area %”, or “related substances” | “Net peptide content”, “assay”, or “peptide by mass” |
| Question answered | How detected peptide-related signals distribute under one separation | What fraction of the weighed material is peptide |
| Units and basis | A relative percentage of integrated peak area | A mass percentage, or a mass per vial or per mg of powder |
| Usual method family | RP-HPLC/UPLC with UV detection [7] | Amino acid analysis, assay, or qualified quantitative LC [4][3] |
| What it cannot stand in for | Peptide mass available for a calculation | Impurity distribution among detected species |
| If the field is absent | Impurity distribution was not reported for this sample | No assayed mass basis exists; the label mass is packaging information |
Purity and content as they appear on a Certificate of Analysis
For the full metric distinction, including mass-balance intuition and research calculations, read peptide purity vs peptide content.
Optional ancillary tests
COAs may include endotoxin (LAL), heavy metals, residual solvents, or water content when those analyses were ordered and reported [2]. USP <85> describes the compendial family for bacterial endotoxins testing when such results appear [5].
Absence of these sections usually means those properties were not tested — not that they were proven acceptable.
What a COA can establish
- Sample-specific analytical findings within the ordered test scope
- Identity evidence when MS or LC-MS data are reported
- Chromatographic purity or impurity profile under the stated method
- Net peptide content or quantity when a content assay is reported
- Presence or absence of specifically ordered ancillary measurements
What a COA does not establish
- Clinical safety, therapeutic efficacy, or suitability for administration
- Legality of possession, sale, or use
- Sterility, unless a sterility-related analysis was ordered
- Manufacturing quality of unanalyzed lots or future batches
- Any property outside the ordered analytical scope
Possession of a COA — from any source — does not by itself guarantee quality, safety, legitimacy, or correctness. Interpret results within method context and research-use boundaries.
Those boundaries are worth learning as a subject in their own right, because most misreadings of peptide data are scope errors rather than arithmetic errors. Our companion resource on what peptide testing does not establish maps where identity, purity, and content results stop, and which questions no chemical measurement answers.
Section-by-section reference
| Section / field | Can help establish | Cannot establish alone |
|---|---|---|
| Sample / lot identification | Traceability between submitted material and reported results | Quality of unanalyzed batches or future lots |
| Identity (MS / LC-MS) | Observed mass or sequence evidence consistent with target | Chromatographic purity; safety; sterility |
| Purity / impurity profile (HPLC) | Relative impurity distribution among detected peptide-related peaks | Identity; net peptide content; clinical suitability |
| Content / quantity (NPC, assay) | Peptide mass fraction or stated quantity basis | Impurity identity for every peak; safety |
| Method reference | Context needed to interpret numerical results | That results are universally transferable across methods |
| Dates and signatures | When analysis was reported; laboratory attribution | Independent third-party status unless clear from source |
COA sections — what they can and cannot establish
Red flags checklist
Use this checklist critically — not as a substitute for reading the full report. A single caution signal may be explainable with context; multiple gaps increase misinterpretation risk.
| Caution signal | Why it matters |
|---|---|
| Generic COA without sample-specific identifiers | Cannot link results to your material or lot |
| Purity reported without method or integration basis | Percentage is not interpretable or comparable |
| Identity missing while purity is prominent | High purity does not prove correct compound |
| No content/NPC when dosing calculations require mass | HPLC % cannot substitute for mass fraction |
| Units ambiguous (per vial vs per mg powder) | Calculation errors and mis-dosing risk |
| Marketing language instead of analytical data | COA should report measurements, not slogans |
| Stale report dates vs received material | Sample and report may not correspond |
| Optional tests implied but not listed | Absence of a metric usually means not tested |
| Safety or sterility claims without matching test | Analytical COAs do not default to biological safety proof |
| No laboratory attribution or report identifier | Harder to verify scope and independence |
| Purity threshold benchmarks without context | “≥99%” without method context is not a universal standard |
| Chromatogram image without integration rules | Visual peak shape alone does not define purity % |
Evaluation signals on peptide COAs
A reading sequence that prevents scope errors
Order matters more than speed. Reading the numbers before the scope is what produces confident conclusions about attributes nobody measured, so the sequence below deliberately front-loads identifiers and scope and leaves interpretation last.
- Confirm the report is sample-specific and matches your material identifiers.
- Read the ordered scope — what was and was not tested — before reading any result.
- Locate the method and integration basis behind each number you intend to use [7][4].
- Check identity evidence orthogonally to purity: mass data and chromatography answer different questions [8][6].
- Match units to your calculation, using content rather than area percent for anything mass-based [4][3].
- Write down what you still do not know — safety, sterility, unanalyzed lots — before the material enters an experimental design.
Worked conceptual read (hypothetical illustration)
The walk-through below uses a fictional report with invented numbers, written purely to show how the sequence above behaves in practice. It is an illustration only: not a VialTests result, not a real sample, and not a benchmark for what any report should show.
- The header carries a client sample identifier and separate receipt and analysis dates, so results can be tied to submitted material — step one is satisfied [2].
- The scope lists identity, purity, and content. No endotoxin or metals line appears, so those properties were not examined and cannot be inferred from what is present [2].
- Identity reports an observed intact mass agreeing with the theoretical value for the intended sequence within a stated tolerance. This supports identity for the analyzed material; it says nothing about how dominant that species is [8].
- Purity reports a hypothetical 97.4% area at 214 nm, with integration rules and a reporting threshold stated. The figure is interpretable because the basis is given — and it remains specific to that method [7][6].
- Content reports a hypothetical 79% net peptide content per milligram of powder. For a mass-based calculation, this is the figure to use; the 97.4% is not a mass fraction [4][3].
- Reading the two together, the roughly 21% of powder mass that is not peptide is unexamined by these tests: counterions, residual moisture, and salts are plausible contributors, but the report does not characterize them [6][4].
- Remaining unknowns after a complete, competent read: sterility, endotoxin burden, biological activity, other vials, and every future lot.
How VialTests COAs fit this framework
Results are issued as a Certificate of Analysis and delivered electronically. Reports describe the sample VialTests analyzed under the ordered catalog service. Core peptide analysis can include identity confirmation, purity assessment, and net peptide content using LC-MS/MS.
VialTests does not publish real customer COAs, order identifiers, or private report URLs on marketing or science pages. Access results through your authorized order pathway after release.
Independent testing option
When supplier documentation is insufficient for your research design, independent testing of a sample you submit can provide separate analytical evidence. Review published catalog services and the peptide testing overview before ordering.
Frequently asked questions
What is a peptide Certificate of Analysis?
A peptide Certificate of Analysis, or COA, is a sample-specific report stating which analyses a laboratory performed on the material it received and what those analyses measured. Depending on the ordered scope it may show identity evidence, a purity or impurity profile, and net peptide content. It documents measurements on one sample rather than certifying a product, a supplier, or an untested attribute.
What should a peptide COA include?
At minimum: identifiers linking the report to the analyzed sample, relevant dates, laboratory attribution, a statement of the ordered scope, and enough method information to interpret each result — including the integration basis behind a purity percentage and the units and basis behind a content value. Results reported without that context are difficult to interpret and impossible to compare across reports.
Does a peptide COA prove identity?
Only when identity was analyzed and reported, and only to the extent the method supports. Mass spectrometry data showing an observed mass consistent with the theoretical value, within a stated tolerance, is identity evidence for the analyzed sample; sequence-supporting fragmentation strengthens it. A purity percentage on its own is not identity evidence, because a dominant peak can still be the wrong compound.
Does a peptide COA prove purity?
It reports purity as measured, which is narrower than proving purity in general. A chromatographic purity figure describes how detected peptide-related peaks distributed under one stated method, above that method's reporting threshold. Impurity classes the method cannot detect are outside the result, so the number is a scoped measurement rather than a guarantee of absolute cleanliness.
What is net peptide content on a COA?
Net peptide content is a mass-fraction result: how much of the weighed or reported sample mass is peptide, once non-peptide components such as counterions, residual moisture, and salts are accounted for. It appears as a mass percentage or as a quantity per vial or per milligram of powder, and it is the appropriate figure for mass-based calculations — chromatographic area percent is not.
Is an HPLC purity percentage enough to trust a peptide?
Not by itself. Purity percent describes chromatographic dominance among detected peptide-related peaks under a stated method. You should also look for sample-specific identifiers, identity evidence, and net peptide content when your calculations require peptide mass.
What is the difference between a supplier COA and independent testing?
A supplier COA reflects the seller’s QC on material they provide. Independent testing analyzes a sample you submit under a separate catalog service with its own scope and methods. Independence and scope differ even when both documents are called a COA.
Does a COA prove a peptide is safe for use in humans?
No. Analytical COAs report measurements within the ordered analysis. They do not establish clinical safety, therapeutic efficacy, or suitability for human or veterinary administration unless a specific safety-related test was ordered and reported.
Why might purity and content both appear on the same COA?
They measure different attributes. Purity addresses impurity profile among detected species. Content addresses peptide mass fraction. Both can be necessary for complete research interpretation.
References
These sources support educational statements on this page. They are not citations of VialTests laboratory ownership, accreditation, or instrument fleet.
- U.S. Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance for Industry. May 2021. Notice of availability, 86 FR 27446 (May 20, 2021). — Official Federal Register notice of availability for the May 2021 FDA guidance. Scope is ANDA pathway considerations for certain highly purified synthetic peptides that refer to listed drugs of rDNA origin — including impurity-profile characterization relative to the reference listed drug — not a general peptide-testing standard. FDA later withdrew the guidance from its active guidance library (July 2026); this citation uses the still-resolving official notice for document identity.
- International Council for Harmonisation. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. — Qualitative specifications concepts for identity, impurities, and assay reporting.
- United States Pharmacopeia. <1503> Quality Attributes of Synthetic Peptide Drug Substances. USP–NF. — Compendial framing for synthetic peptide quality attributes including content and impurity concepts.
- Hoofnagle AN, et al. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry–based assays. Clinical Chemistry. 2016;62(1):48–69. — Discusses net peptide content, amino acid analysis, and peptide handling for quantitative work.
- United States Pharmacopeia. <85> Bacterial Endotoxins Test. USP–NF. — Compendial endotoxin testing referenced when COAs report LAL-based endotoxin results.
- D'Hondt M, et al. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. — Reviews peptide impurity classes and analytical context for synthetic peptide quality.
- United States Pharmacopeia. <621> Chromatography. USP–NF. — General chromatographic principles applicable to HPLC/UPLC peptide separations.
- Zeng K, Geerlof-Vidavisky I, Gucinski A, Jiang X, Boyne MT. Liquid chromatography–high resolution mass spectrometry for peptide drug quality control. The AAPS Journal. 2015;17(3):643–651. — Demonstrates LC-HRMS for peptide identity, impurity detection, and sequence-related characterization in quality-control context.
Need Independent Peptide Testing?
If you need sample-specific analytical evidence
Beyond supplier documentation, review published catalog services and the customer workflow.